IN DEMENTIA WITH LEWY BODIES, BRAAK STAGE DETERMINES PHENOTYPE, NOT LEWY BODY DISTRIBUTION
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Weisman et al.1 reported the validation of revised neuropathologic criteria for dementia with Lewy bodies (DLB) proposed by the Consortium for Dementia with Lewy Bodies.2 In their analysis, they incorrectly assess the application of the new neuropathologic criteria.
The new recommendations for neuropathologic diagnosis of DLB propose that the neuropathologic assessment should generate a probability statement about the likelihood that the pathology would be associated with the DLB clinical syndrome. The probability is positively related to the extent of Lewy body pathology (increasing from brainstem to limbic to diffuse Lewy body types) and negatively related to the severity of Alzheimer type pathology (decreasing from high to intermediate to low likelihood Alzheimer disease [AD]).
Evidence available at the time of the formulation of the criteria suggested that many cases in both the intermediate and high probability groups would have the DLB syndrome. In the report by Weisman et al., they classified cases of diffuse Lewy body disease and high likelihood AD (Braak stages V–VI) as “low probability DLB,” but the classification should be “intermediate probability DLB.”2
The frequency …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.